Methods for treating Filoviridae virus infections

A method of treating a Filoviridae infection in a human in need thereof comprising administering a therapeutically effective amount of a compound of Formula IV:

• or a pharmaceutically acceptable salt thereof;
• wherein,
• R7 is selected from the group consisting of
• a) H, —C(═O)R11, —C(═O)OR11, —C(═O)NR11R12, —C(═O)SR11, —S(O)R11, —S(O)2R11, —S(O)(OR11), —S(O)2(OR11), or —SO2NR11R12;
• c) a group selected from:
• wherein:
• Rc is selected from the group of phenyl, 1-naphthyl, 2-naphthyl,
• Rd is selected from the group of H and CH3;
• Re1 and Re2 are each independently selected from the group of H, (C1-C6)alkyl and benzyl;
• Rf is selected from the group of H, (C1-C8)alkyl, benzyl, (C3-C6)cycloalkyl, and —CH2—(C3-C6)cycloalkyl;
• Rg is selected from the group of (C1-C8)alkyl, —O—(C1-C8)alkyl, benzyl, —O-benzyl, —CH2—(C3-C6)cycloalkyl, —O—CH2—(C3-C6)cycloalkyl, and CF3;
• and
• n′ is an integer selected from the group of 1, 2, 3, and 4;
• and
• d) a group of the formula:
• wherein:
• Q is selected from the group of O, S, NR, +N(O)(R), N(OR), +N(O)(OR), and N—NR2;
• Z1 and Z2, when taken together, are -Q1(C(RY)2)3Q1-;
• wherein
• each Q1 is independently selected from the group of O, S, and NR;
• and
• each Ry is independently selected from the group of H, F, Cl, Br, I, OH, R, —C(=Q2)R, —C(=Q2)OR, —C(=Q2)N(R)2, —N(R)2, —+N(R)3, —SR, —S(O)R, —S(O)2R, —S(O)(OR), —S(O)2(OR), —OC(=Q1)R, —OC(=Q2)OR, —OC(=Q2)(N(R)2), —SC(=Q2)R, —SC(=Q2)OR, —SC(=Q2)(N(R)2), —N(R)C(=Q2)R, —N(R)C(=Q2)OR, —N(R)C(=Q2)N(R)2, —SO2NR2, —CN, —N3, —NO2, —OR, and Z3;
• or when taken together, two Ry on the same carbon atom form a carbocyclic ring of 3 to 7 carbon atoms;
• each Q2 is independently, O, S, NR, +N(O)(R), N(OR), +N(O)(OR), or N—NR2;
• or
• Z1 and Z2 are each, independently, a group of the Formula Ia:
• wherein:
• each Q3 is independently selected from the group of a bond, O, CR2, NR, +N(O)(R), N(OR), +N(O)(OR), N—NR2, S, S—S, S(O), and S(O)2;
• M2 is an integer selected from the group of 0, 1 and 2;
• each Rx is independently Ry or the formula:
• wherein:
• each M1a, M1c, and M1d is an integer independently selected from the group of 0 and 1;
• M12c is an integer selected from the group of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12;
• Z3 is Z4 or Z5;
• Z4 is R, —C(Q2)Ry, —C(Q2)Z5, —SO2Ry, or —SO2Z5;
• and
• Z5 is a carbocycle or a heterocycle wherein Z5 is independently substituted with 0 to 3 Ry groups;
• each R11 or R12 is independently H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C4-C8)carbocyclylalkyl, (C6-C20)optionally substituted aryl, optionally substituted heteroaryl, —C(═O)(C1-C8)alkyl, —S(O)n(C1-C8)alkyl or (C6-C20)aryl(C1-C8)alkyl;
• or R11 and R12 taken together with a nitrogen to which they are both attached form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with —O—, —S—or —NRa—;
• each Ra is independently selected from the group of H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C6-C20)aryl(C1-C8)alkyl, (C4-C8)carbocyclylalkyl, —C(═O)R, —C(═O)OR, —C(═O)NR2, —C(═O)SR, —S(O)R, —S(O)2R, —S(O)(OR), —S(O)2(OR), and —SO2NR2;
• wherein
• each R is independently selected from the group of H, (C1-C8) alkyl, (C1-C8) substituted alkyl, (C2-C8)alkenyl, (C2-C8) substituted alkenyl, (C2-C8) alkynyl, (C2-C8) substituted alkynyl, (C6-C20)aryl, (C6-C20)substituted aryl, (C2-C20)heterocyclyl, (C2-C20)substituted heterocyclyl, (C6-C20)aryl(C1-C8)alkyl and substituted (C6-C20)aryl(C1-C8)alkyl;
• each n is an integer independently selected from the group of 0, 1, and 2;
• and
• wherein each (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl or (C6-C20)aryl(C1-C8)alkyl of each R11 or R12 is, independently, optionally substituted with one or more substituents selected from the group of halo, hydroxy, CN, N3, N(Ra)2 and ORa;
• and wherein one or more of the non-terminal carbon atoms of each said (C1-C8)alkyl may be optionally replaced with —O—, —S—or —NRa—.